COMMUNIQUÉS West-GlobeNewswire

-
DBV Technologies annonce l'acceptation par la FDA du dépôt de sa demande de sa Licence Biologique pour Viaskin Peanut, un traitement de l'allergie aux arachides
04/10/2019 -
Pixium Vision provides clarification on Omnes Capital shareholding, unchanged since end 2017
04/10/2019 -
Pixium Vision apporte des précisions sur la participation de Omnes Capital, inchangée depuis fin 2017
04/10/2019 -
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
04/10/2019 -
Conformis Announces Departure of Paul Weiner, CFO
04/10/2019 -
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Camelina Platform for Producing PHB Biomaterials to Improve Water Quality at International Scientific Conference
04/10/2019 -
Assure Holdings Announces Issuance of Options Under Stock Option Plan
04/10/2019 -
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
04/10/2019 -
Cynata Advances Toward Phase 2 Clinical Trial of Cymerus(TM) MSCs in Patients with Osteoarthritis
04/10/2019 -
Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.
04/10/2019 -
Optinose Appoints Michael Richardson to New Position of Vice President, Business Development
04/10/2019 -
Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
04/10/2019 -
Emerald Health Therapeutics’ Joint Venture Pure Sunfarms Begins Shipping Branded Cannabis Product to British Columbia Provincial Wholesaler
04/10/2019 -
United Health Products Announces Submission of Premarket Approval (PMA) Application to the U.S. FDA for the HemoStyp® Device for Use in Surgical Procedures
04/10/2019 -
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
04/10/2019 -
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
04/10/2019 -
Statement re: Appointment of Corporate Broker
04/10/2019 -
Press news Biocartis Group NV: Disclosure of a transparency notification
04/10/2019 -
NOTICE TO DISREGARD – Dabir Surfaces
04/10/2019
Pages